The High Authority for Health (HAS) refused, on September 9, early access to the Leqembi (Lecanémab), a monoclonal antibody against Alzheimer which is aimed at people affected by the disease at a light stage. This means that it will not be available in France, at least not immediately. A decision that disappointed patient associations and surprised certain specialists. In his opinion, the HAS justifies its refusal by an efficiency “Not clinically relevant to the disease associated with a worrying tolerance profile”. However, the European Union, after initially refused its green light, gave a European marketing authorization (AMM) to Leqembi in April, restricting it to patients least at risk of serious adverse effects.
Let us recall that this very heterogeneous disease, which sometimes begins insidiously, reaches cognitive functions, whose memory, and can be associated with personality disorders, a drop in motivation, etc. It generally evolves towards a loss of autonomy, which also constitutes a burden for their caregivers. According to the France Alzheimer organization, more than 1.4 million people are affected in France.
You have 86.22% of this article to read. The rest is reserved for subscribers.
